Rougier P, Ychou M, Droz J P
Service de gastro-entérologie, Institut Gustave-Roussy, Villejuif, France.
Bull Cancer. 1988;75(10):979-81.
Fifteen patients with hepatocellular carcinoma were administered elliptinium acetate in a phase II trial. A dose of 80 mg/m2/day was administered during 3 consecutive days, every 3 weeks. According to WHO criteria regarding response, no objective responses were observed. The major toxicity was dryness of the mouth which occurred in 73% of patients, on addition, one case of hemolysis was documented in spite of a systematic search for anti-elliptinium antibodies prior to each injection. In conclusion, elliptinium acetate has no valuable therapeutic impact on the treatment of hepatocellular carcinoma.
在一项II期试验中，对15例肝细胞癌患者给予醋酸椭圆玫瑰树碱。每3周连续3天给予80mg/m²/天的剂量。根据世界卫生组织关于反应的标准，未观察到客观反应。主要毒性是口干，73%的患者出现口干，此外，尽管在每次注射前系统地检测抗醋酸椭圆玫瑰树碱抗体，但仍记录到1例溶血病例。总之，醋酸椭圆玫瑰树碱对肝细胞癌的治疗没有有价值的治疗作用。
